Total Compensation: $ 3.05 M
Dr. Squires is the Interim Chairman and Chief Executive Officer of Biovail Corporation. Dr. Squires became Interim Chairman effective June 30, 2007. Dr. Squires has served on our Board of Directors since June 29, 2005. Before joining us in November 2004, Dr. Squires spent six years at MDS Inc. ("MDS"), a publicly traded company listed on the NYSE and the Toronto Stock Exchange ("TSX"), the last three as President and Chief Executive Officer of MDS Pharma Services, a business unit of MDS, which provides drug-discovery and development services to pharmaceutical and biotechnology companies. Before joining MDS, Dr. Squires spent more than 22 years with The Upjohn Company and Pharmacia & Upjohn Inc., where he held multiple senior positions in Canada, the U.S. and the Pacific Rim. He received his B.Sc. from the University of Toronto and his Ph.D. in biophysics from the University of London, Institute of Cancer Research.
Total Compensation: $ 653,816.00
Mr. Godin is Executive Vice-President and Chief Operating Officer of Biovail Corporation. Mr. Godin is responsible for our commercial, scientific and product-development capabilities, as well as our manufacturing, contract-development and business development services. Mr. Godin joined us in April 2006 from MDS Pharma Services, a contract research organization that provides drug-discovery and development services to pharmaceutical and biotechnology companies, where he held a series of progressively responsible executive positions in Canada and the U.S., including from October 2004 to April 2006, when he served as President of MDS Pharma Services, a business unit of MDS. Before joining MDS Pharma Services in 1999, Mr. Godin spent eight years with Schering-Plough Corporation, a publicly traded company listed on the NYSE, where he held the technical leadership position in Canada and a business-unit management role in France. He has also held several positions with business and operational accountabilities during his seven-year tenure at L'Oreal Canada Inc. Mr. Godin has a M.B.A. from Concordia University in Montreal. He also holds an engineering degree from Sherbrooke University in Quebec.
Total Compensation: $ 610,869.00
Mr. Howling is Senior Vice-President and Chief Financial Officer of Biovail Corporation. Mr. Howling has responsibility for finance, including consolidated financial planning and reporting, and financial operations. His responsibilities also include the development of strategies and programs to proactively position our Company and business to disparate groups of external stakeholders, including the investment community, media, governments, the medical community and the general public. Mr. Howling, who joined us in 1997, was previously Senior Vice-President, Finance and Corporate Affairs. Before coming to our Company, he was Vice-President and Chief Financial Officer at Pharma Patch Plc. Previously, Mr. Howling occupied senior financial management positions at Roberts Company Canada Limited, including General Manager, Corporate Secretary and Controller. His previous experience includes financial and general management positions with SmithKline Beecham plc, a publicly traded company listed on the NYSE and London Stock Exchange, Bencard Allergy Laboratories, McGraw-Edison and Price Waterhouse. Mr. Howling passed the New Jersey Certified Public Accountant exams and received his accounting degree from Upsala College, New Jersey.
Total Compensation: $ 605,784.00
Ms. Kelley is Senior Vice-President, General Counsel and Corporate Secretary of Biovail Corporation. She is responsible for our legal operations, including corporate governance, securities compliance, mergers and acquisitions, intellectual property, litigation, patent law, legal policies and legal support for our business units. She also serves as Corporate Secretary to the Board of Directors. Prior to joining us in August 2006, Ms. Kelley was Vice-President, Associate General Counsel and Principal Reputation Risk Officer for BMO Financial Group. Her responsibilities included enterprise-wide responsibility for corporate governance, legal and reputation risk management, regulatory relationship management, and management of all securities litigation and regulatory enforcement issues. Previously, she was Managing Director and Associate General Counsel for BMO Nesbitt Burns Inc., a Canadian wealth-management firm and the North American investment and corporate banking division of BMO Financial Group, a publicly traded company listed on the TSX and NYSE, where she oversaw all litigation, securities policy development and regulatory enforcement, including management of several large international securities class actions and an analyst fraud case. Prior to her roles at BMO Nesbitt Burns Inc., she was a lawyer at Torys LLP, an international law firm. Ms. Kelley received her LL.B. from Queen's University in Kingston, Ontario, Canada. Ms. Kelley is called to the Bars in the provinces of Ontario and Saskatchewan.
Total Compensation: $ —
Ms. Brown is the Vice-President, Associate General Counsel and Chief Compliance Officer and is responsible for corporate commercial, transactional and securities related legal work. Ms. Brown is the Chair of the Company's Disclosure Committee and, as Chief Compliance Officer, she is responsible for legal and regulatory compliance, Enterprise Risk Management and administrative oversight of Internal Audit. Ms. Brown came to Biovail in September 2005 from Alliance Atlantis Communications Inc. where she held the position of Senior Vice President, Business & Legal Affairs, and was responsible for managing the business and legal affairs for Alliance Atlantis' broadcast operations. Ms. Brown is called to the Bar in the Province of Ontario and is a member of the Law Society of Upper Canada and the Canadian Bar Association. She received her law degree from Dalhousie University in Halifax, Nova Scotia in 1990. She also holds a B.A. (Hons.) in Political Studies from Queen's University in Kingston, Ontario.
Total Compensation: $ —
Mr. Miszuk has been Vice-President, Controller and Assistant Secretary since June 2000. Mr. Miszuk joined the Company in July 1990 as Controller of an affiliate company and was appointed Corporate Controller in March 1994. In November 1997 he was appointed Vice President, Controller. Prior to joining Biovail, Mr. Miszuk occupied senior financial management positions for Becton Dickinson Canada Inc. including Manager of Planning and Analysis and Manager of Financial Accounting. His previous experience includes financial positions with Intercraft Industries Canada and Fruehauf Canada Inc.
Total Compensation: $ 1.86 M
—
Total Compensation: $ 597,500.00
Mr. Gubitz is Senior Vice-President, Corporate Development of Biovail Corporation. Mr. Gubitz investigates growth opportunities and other initiatives that will enable our company to maximize the value of current and future investments. He also assists our company in our strategic-planning process. Mr. Gubitz joined us in March 2006 from MDS Capital Corp. ("MDS Capital"), a North American venture-capital company focused exclusively on life sciences, where he was Chief Operating Officer. He spent 10 years with MDS Capital in various senior roles, with accountability for all operational matters, institutional fundraising, investor relations, finance and legal affairs. Mr. Gubitz also became Chairman of MDS Capital's Investment Committee in 2004. Before joining MDS Capital in 1996, Mr. Gubitz was a partner practicing corporate and securities law at Fasken Martineau Du Moulin LLP. He was called to the Bar in the province of Ontario in 1984. Mr. Gubitz holds an LL.B. and a B.A. from McGill University in Montreal.
Total Compensation: $ —
Mr. Segal was appointed to the Board of Directors in December 2007. Mr. Segal is the Chief Executive Officer and a director of Thallion Pharmaceuticals Inc. ("Thallion"), a public company listed on the TSX. Mr. Segal served as President and Chief Executive Officer of Caprion Pharmaceuticals Inc. from 1998 until its merger with Ecopia BioSciences Inc. to form Thallion in 2007. Mr. Segal was previously a management consultant with McKinsey & Company and President and Chief Executive Officer of Advanced Bioconcept Ltd., which was sold to NEN Life Sciences Products, Inc. (now PerkinElmer, Inc.) in 1998. Mr. Segal currently serves on the board of GBC North American Growth Fund Inc. and on the Advisory Council of the School of Science at Brandeis University. Mr. Segal has previously served on boards of both public and private companies in the U.S. and Canada. Mr. Segal earned a B.A. in politics from Brandeis University and an M.B.A. from Harvard Business School.
Total Compensation: $ —
Mr. Bristow has been a Director of Biovail Corporation since the amalgamation of our predecessors, Trimel Corporation and BCI, in 1994. From January 1993 to February 1994, he was a director of BCI. Mr. Bristow is a financial advisor at Raymond James Ltd. ("Raymond James"), a Canadian investment banking firm, where he has provided independent financial services since January 28, 2008. Prior to his current position at Raymond James, Mr. Bristow was a Vice President and senior investment advisor at BMO Nesbitt Burns Inc., a Canadian investment banking firm, from December 1991 until his retirement on June 30, 2006. From September 1975 to December 1991, he served as Vice President and director of Richardson Greenshields of Canada Limited, an investment banking firm.
Total Compensation: $ —
Mr. Wells was elected to the Board of Directors in June 2005. Mr. Wells became the Lead Director effective June 30, 2007. Mr. Wells is currently the Chief Financial Officer of Loblaw Companies Limited ("Loblaw"), a publicly traded company listed on the TSX, Canada's largest food distributor and a leading provider of general merchandise products, drugstore products, and financial products and services. In addition to his current position at Loblaw, Mr. Wells also serves as a director or officer of a number of subsidiaries of Loblaw. Prior to his current position at Loblaw, Mr. Wells served as Chief Financial Officer of Bunge Limited ("Bunge"), a U.S.-headquartered company, whose shares are listed on the NYSE, in the global agribusiness, fertilizer and food product industries, and has served as a director or officer of a number of other subsidiaries and joint ventures of Bunge since January 2000. Mr. Wells is versed in corporate governance matters, having led Bunge's initial public offering on the NYSE, managed its SOX compliance process and overseen its investor relations program. Prior to joining Bunge, Mr. Wells spent 10 years in senior financial management at McDonald's Corporation, a publicly traded company listed on the NYSE and the Chicago Stock Exchange, in the U.S. and Brazil. Mr. Wells is currently a member of the Standard & Poor's Corporate Issuer Advisory Board, a Trustee and a member of the audit committee of The Lakefield College School Foundation, and a member of the investment committee of the Uruguay International Venture Capital Fund.
Total Compensation: $ —
Mr. Sokalsky was elected to the Board of Directors in June 2005. He assumed the responsibilities of Executive Vice President and Chief Financial Officer of Barrick Gold Corporation ("Barrick"), a publicly traded company listed on the TSX and NYSE, a gold mining and exploration company, in May 2004. Previously, Mr. Sokalsky had been the Senior Vice President and Chief Financial Officer of Barrick since March 1999 and Vice President and Treasurer, directing the financial operations of Barrick, since December 1993. Prior to joining Barrick, Mr. Sokalsky spent 10 years in various financial capacities at George Weston Ltd., a TSX-listed company. Mr. Sokalsky has a B.Comm. (Hons.) degree from Lakehead University and received his chartered accountant designation in 1982.
Total Compensation: $ —
Mr. Van Every was elected to the Board of Directors in June 2004. Mr. Van Every is a chartered accountant and was, until 2004, a partner in the professional services firm of PricewaterhouseCoopers LLP. He has practiced public accounting since 1966. From 1969 to 1998, he was a partner of Coopers & Lybrand, one of the predecessor firms of PricewaterhouseCoopers LLP. During that period, he served for various periods as Partner in Charge of an office, a member of the Management Committee, a member of the Partnership Board and Chair of the Partnership Audit and Governance Committees. Mr. Van Every has been lead engagement partner responsible for audit and other services to a number of public and private companies. He is also a member of the boards of Kelman Technologies Inc. (a TSX-listed company), Woods Canada Limited (which was formed as a result of the merger in 2007 of Woods Canada Limited and Erewhon Brands International Limited, two companies of which Mr. Van Every was a member of the board prior to this merger) and The Jockey Club of Canada. Mr. Van Every has completed the Director Education Program sponsored by the Rotman School of Management and the Institute of Corporate Directors, and has received his ICD.D, the professional designation for directors in Canada.
Total Compensation: $ —
Ms. Mayer is Senior Vice-President, Business Development Services at BPI. Ms. Mayer is responsible for leading the Business Development Services Team, which provides services in respect of identifying and analyzing new opportunities for us. Ms. Mayer joined us in May 2005 and was promoted to her current position effective January 1, 2007. Ms. Mayer has over 20 years of broad business experience in the pharmaceutical industry across many disciplines and therapeutic areas. Before joining us, she was Vice President of Global Business Development at sanofi-aventis (formerly Aventis), a publicly traded company listed on the NYSE, where she spent five years. Prior to that, she worked for 13 years at Johnson & Johnson, a publicly traded company listed on the NYSE, in the pharmaceutical sector, holding positions in various disciplines, including business development, marketing, sales and finance. Ms. Mayer also has four years of previous experience in large public accounting firms. Ms. Mayer holds an M.B.A. from Rutgers University in New Jersey and a B.A. from Glassboro College (now Rowan University) in New Jersey.
Total Compensation: $ —
Mr. Chouinard is Chief Operating Officer of BLS in Barbados, and a member of its Board of Managers. He is responsible for the management, direction and control of all aspects of BLS' business. Mr. Chouinard came to us in March 2000 from BioChem Pharma Inc., where he was Vice President of Global Commercialisation for vaccines for approximately three years. Prior to that he spent 18 years with American Cyanamid Company (Lederle), GlaxoSmithKline Inc. and Abbott, and held senior commercial and operations positions in the U.S. and Canada. Since joining our company, Mr. Chouinard has held the positions of Vice President and General Manager of BPC and Vice President, Manufacturing Planning and Strategy of Biovail Corporation, before joining BLS in February 2006. Mr. Chouinard holds a B.A. in economics from McGill University in Montreal.
Total Compensation: $ —
Mr. Bovaird is Vice-President, Corporate Finance and is responsible for the management of corporate business planning and forecasting activities, the financial aspects of the corporate strategic-planning process, and the financial analysis of specific business opportunities. Additionally, Mr. Bovaird is responsible for Biovail's income tax planning and compliance. Mr. Bovaird, who previously held the position of Vice-President, Taxation at Biovail, served as a consultant to the Company in 2000 and 2001. Before coming to Biovail, he was Director, Special Projects, at Molson, Inc. Mr. Bovaird is a Chartered Accountant and holds a Bachelor of Mathematics (Hons.) degree from the University of Waterloo.
Total Compensation: $ —
Mr. de Saldanha is Vice-President, Finance and Treasurer. Mr. de Saldanha works closely with the Chief Financial Officer to support Board-related matters and other Finance initiatives. He is also responsible for all treasury functions at Biovail. Mr. de Saldanha joined Biovail in 2001 as Vice-President, Controller of Biovail Pharmaceuticals Canada, the Company's Canadian sales and marketing division. He also served as Vice-President, Manufacturing Finance before assuming his current role. Before coming to Biovail, Mr. de Saldanha spent more than seven years with Molson Inc., where he held a series of progressively senior finance positions, including Vice-President, Controller. Mr. de Saldanha, whose work experience includes positions with professional accounting and auditing firms in Canada, the United Kingdom and South Africa, is a Chartered Accountant. He received his Commerce and Accounting degrees from the University of Witwatersrand in South Africa.
Total Compensation: $ —
Mr. Durham is Senior Vice President, Corporate Human Resources and Information Technology of Biovail Corporation, and joined us as Vice-President, Corporate Human Resources in February 2003. Mr. Durham came to us from Pharmacia Corporation, where he served as Vice-President for Human Resources for Global Marketing and North American country operations from 2000 to 2003. Prior to that time he spent 15 years with Pharmacia & Upjohn Inc. and held senior human resource positions in the U.S., Asia and Canada. In addition to human resources, Mr. Durham has held positions in manufacturing and sales operations. Mr. Durham is a graduate of Carleton University in Ottawa, where he received his B.A. Hons. in political science and economics.
Total Compensation: $ —
Mr. Sebben is Vice-President, Manufacturing. Mr. Sebben is responsible for all aspects of the production and manufacture of Biovail medicines. Mr. Sebben, who came to Biovail in July 2004, was previously Vice-President, Operations, at TorPharm, a Toronto-based division of Apotex Inc. Before that, Mr. Sebben spent more than 13 years at GlaxoSmithKline in Mississauga, where he held a series of progressively responsible senior positions, including Director, Operations and Director, Supply Chain. His experience also includes senior materials-management and business-planning positions with Sandoz Canada and Travenol Canada. Mr. Sebben holds a Master of Business Administration degree from York University in Toronto, and a Bachelor of Science degree from the University of Toronto.
Scott Smith - Vice President, Subsidiary/General Manager, Subsidiary
Total Compensation: $ —
Mr. Smith is Vice-President and General Manager, Biovail Pharmaceuticals, Inc. Mr. Smith is responsible for Sales and Marketing operations for the U.S. Division. Commencing in 2007, Mr. Smith also became Vice President, General Manager, Biovail Pharmaceuticals Canada in which capacity he will be responsible for Sales and Marketing activities in Canada. Beginning his pharmaceutical career in 1987, Mr. Smith held increasingly responsible positions, including Vice President, Sales & Marketing Canada and Vice President, U.S. Sales, Mid-West Region for Upjohn, Pharmacia & Upjohn and Pharmacia. During this time, Mr. Smith gained global experience by accepting a series of sales and marketing leadership roles in countries including: Hong Kong, China, Malaysia, Singapore, Vietnam, Canada, and several in Europe. Mr. Smith holds a Masters of International Business degree from the American Graduate School of International Management and received two Bachelors degrees in Chemistry/Biology and Pharmacology/Toxicology from the University of Western Ontario.
Total Compensation: $ —
Dr. Paul was elected to the Board of Directors in June 2002. Dr. Paul is a founding principal of Laurel Crown Partners, LLC ("Laurel Crown"), a leveraged buyout and principal investment company based in Los Angeles, CA. Prior to his work at Laurel Crown and its predecessor, Dr. Paul was a managing director at Donaldson, Lufkin & Jenrette, Inc. ("DLJ"), a New York-based securities and brokerage firm, and then at Credit Suisse First Boston, after its purchase of DLJ. At DLJ, Dr. Paul was responsible for building and overseeing much of the firm's efforts in the life sciences sector. Dr. Paul received his B.A. and M.D. from Harvard University and subsequently received his M.B.A. from Stanford University. Dr. Paul sits on the boards of Ampco-Pittsburgh Corporation, a public company listed on the NYSE and the Philadelphia Stock Exchange, Harvard Medical School and the American Red Cross, of which Dr. Paul also serves as a member of the compensation committee. In addition, he serves as a board member for some of Laurel Crown's portfolio companies, including Global Fitness, the largest franchisee of Gold's Gym, and P&P Realty, a real estate development company.
